Live Breaking News & Updates on Cardiometabolic Medicine

Stay updated with breaking news from Cardiometabolic medicine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

University of Manchester: Best statins for reducing cardiovascular risk in people with diabetes found

Three commonly prescribed statins are best placed to lower all the ‘bad’ types of cholesterol and prevent cardiovascular disease in people with diabetes, according to a statistical combination of the results of 42 clinical trials.The study was carrie ....

United Kingdom , Alexander Hodkinson , Martin Rutter , National Institute For Health , National Institute For Health Research , Metabolism Centre , Manchester University , Keele University , University Of Manchester , Foundation Trust , National Institute , Health Research , Care Excellence , British Medical Journal , Cardiometabolic Medicine , Honorary Consultant Physician , Manchester Royal Infirmary ,

Best statins for reducing cardiovascular risk in people with diabetes found

Best statins for reducing cardiovascular risk in people with diabetes found
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Alexander Hodkinson , Martin Rutter , National Institute For Health , National Institute For Health Research , Metabolism Centre , Manchester University , Keele University , University Of Manchester , Foundation Trust , National Institute , Health Research , Care Excellence , British Medical Journal , Cardiometabolic Medicine , Honorary Consultant Physician , Manchester Royal Infirmary ,

Empagliflozin trial halted after successful outcome in CKD

An early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD). ....

Richard Haynes , William Herrington , Waheed Jamal , Boehringer Ingelheim Eli Lilly , Clinician Scientist Oxford Population Health , University Of Oxford , Boehringer Ingelheim , Population Health Research Unit , Eli Lilly , Health Research Unit , Associate Professor William Herrington , Honorary Consultant Nephrologist , Professor Richard Haynes , Principal Investigator , Corporate Vice President , Cardiometabolic Medicine ,

Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

Press release content from Business Wire. The AP news staff was not involved in its creation. ....

Rheinland Pfalz , United States , Stephan Thalen , Richard Haynes , Colin Baigent , Waheed Jamal , Sarah Reimer , Anne Whitehouse , Eli Lilly , Martin Landray , William Herrington , Jeff Emmick , University Of Oxford , Steering Committee , Oxford Population Health , Boehringer Ingelheim , Data Monitoring Committee , Population Health Research Unit , Product Development , Clinician Scientist Oxford Population Health , Research Council , Independent Data Monitoring , Medical Research Council , Health Research Unit , Associate Professor William Herrington , Honorary Consultant Nephrologist ,

Empagliflozin benefits adults hospitalised for acute heart failure

Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin. ....

Adriaan Voors , Waheed Jamal , Eli Lilly , University Medical Center , European Union , Boehringer Ingelheim , National Readmission Database , Kansas City Cardiomyopathy Questionnaire , Empulse Principal , National Readmission , Corporate Vice President , Cardiometabolic Medicine ,